|
|
|
|
| LEADER |
01571nam a22003015i 4500 |
| 001 |
000286103 |
| 005 |
20210510080704.0 |
| 007 |
cr nn 008mamaa |
| 008 |
131114s2014 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783034807098
|
| 024 |
7 |
|
|a 10.1007/978-3-0348-0709-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Indacaterol :
|b The First Once-daily Long-acting Beta2 Agonist for COPD /
|c edited by Alexandre Trifilieff.
|
| 250 |
|
|
|a 1st ed. 2014.
|
| 260 |
# |
# |
|a Basel :
|b Springer Basel :
|b Imprint: Springer,
|c 2014.
|
| 300 |
|
|
|a VII, 146 p. 41 illus., 21 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a Current Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies – lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD? .
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Respiratory organs—Diseases.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Pneumology/Respiratory System.
|
| 700 |
1 |
|
|a Trifilieff, Alexandre.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|